Financials in USD. Standardized financial statements.
A compact view of how Relay Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $15.36M | $10.01M | $25.55M | $1.38M | $3.03M | $82.65M | $0 | $0 |
| Revenue Growth? | +53.4% | -60.8% | +1749.8% | -54.4% | -96.3% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $3.56M | $0 | $0 | $0 | $0 | $3.55M | $2.85M | $2.15M |
| Gross Profit? | $11.80M | $10.01M | $25.55M | $1.38M | $3.03M | $79.11M | -$2.85M | -$2.15M |
| Gross Margin? | +76.8% | +100.0% | +100.0% | +100.0% | +100.0% | +95.7% | 0.0% | 0.0% |
| Operating Expenses? | $314.54M | $382.48M | $398.55M | $300.66M | $367.73M | $134.90M | $84.05M | $49.89M |
| Operating Income? | -$302.74M | -$372.47M | -$373.00M | -$299.27M | -$364.70M | -$55.80M | -$84.05M | -$49.89M |
| EBITDA? | -$272.92M | -$380.21M | -$374.15M | -$306.82M | -$223.08M | -$52.25M | -$81.20M | -$47.73M |
| Income Before Tax | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M | -$52.41M | -$75.31M | -$48.78M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M | -$52.41M | -$66.50M | -$48.78M |
| EPS? | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-2.56 | $-15.53 | $-19.63 |
| Diluted EPS? | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-2.56 | $-15.53 | $-19.63 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality